SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ArriVent Presents Initial Phase 1 Data for ARR-217

ArriVent Biopharma presented initial Phase 1 data for ARR-217 in advanced solid tumors.

AVBP

Related stories